A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Ana de la Fuente 1 , Marta Santisteban 2 3 , Josep Lupón 4 5 6 , José Manuel Aramendía 2 3 , Agnes Díaz 1 3 , Ana Santaballa 7 , Amparo Hernándiz 8 , Pilar Sepúlveda 4 8 , Germán Cediel 5 , Begoña López 3 4 9 , José María López Picazo 2 , Manuel M Mazo 3 10 , Gregorio Rábago 1 , Juan José Gavira 1 3 , Ignacio García-Bolao 1 3 , Javier Díez 1 3 4 9 , Arantxa González 3 4 9 , Antoni Bayés-Genís 4 5 6 11 , Susana Ravassa 3 4 9
Anthracycline-based cancer chemotherapy (ACC) causes myocardial fibrosis, a lesion contributing to left ventricular dysfunction (LVD). We investigated whether the procollagen-derived type-I C-terminal-propeptide (PICP): (1) associates with subclinical LVD (sLVD) at 3-months after ACC (3m-post-ACC); (2) predicts cardiotoxicity 1-year after ACC (12m-post-ACC) in breast cancer patients (BC-patients); and (3) associates with LVD in ACC-induced heart failure patients (ACC-HF-patients).
Echocardiography, serum PICP and biomarkers of cardiomyocyte damage were assessed in two independent cohorts of BC-patients: CUN (n = 87) at baseline, post-ACC, and 3m and 12m (n = 65)-post-ACC; and HULAFE (n = 70) at baseline, 3m and 12m-post-ACC. Thirty-seven ACC-HF-patients were also studied. Global longitudinal strain (GLS)-based sLVD (3m-post-ACC) and LV ejection fraction (LVEF)-based cardiotoxicity (12m-post-ACC) were defined according to guidelines. BC-patients: all biomarkers increased at 3m-post-ACC versus baseline. PICP was particularly increased in patients with sLVD (interaction-p < 0.001) and was associated with GLS (p < 0.001).
PICP increase at 3m-post-ACC predicted cardiotoxicity at 12m-post-ACC (odds-ratio ≥ 2.95 per doubling PICP, p ≤ 0.025) in both BC-cohorts, adding prognostic value to the early assessment of GLS and LVEF. ACC-HF-patients: PICP was inversely associated with LVEF (p = 0.004). In ACC-treated BC-patients, an early increase in PICP is associated with early sLVD and predicts cardiotoxicity 1 year after ACC. PICP is also associated with LVD in ACC-HF-patients.
CITA DEL ARTÍCULO Cancers (Basel). 2022 Jun 14;14(12):2941. doi: 10.3390/cancers14122941